Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements. It is designed to disrupt the interaction between menin and KMT2A (also known as MLL), which plays a role in the pathogenesis of these leukemias. It is taken by mouth.
History, Community, Culture & Applications
Explore the main themes, entities and connections around Revumenib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
kmt2a treatment acute name us drug menin gene 2024 leukemias adverse medical revuforj administration leukemia lysine methyltransferase 2a differentiation syndrome
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Revumenib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Revumenib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Revumenib | ATC code | L01XX87 (WHO) | 1.00 | infobox |
| Revumenib | CAS Number | 2169919-21-3 | 1.00 | infobox |
| Revumenib | CAS Number | 2169919-22-4 | 1.00 | infobox |
| Revumenib | ChEMBL | ChEMBL4650827 | 1.00 | infobox |
| Revumenib | ChEMBL | ChEMBL4650278 | 1.00 | infobox |
| Revumenib | ChemSpider | 95502909 | 1.00 | infobox |
| Revumenib | Drug class | Antineoplastic; menin inhibitor | 1.00 | infobox |
| Revumenib | DrugBank | DB18515 | 1.00 | infobox |
| Revumenib | DrugBank | DBSALT003460 | 1.00 | infobox |
| Revumenib | Formula | C32H47FN6O4S | 1.00 | infobox |
| Revumenib | KEGG | D12728 | 1.00 | infobox |
| Revumenib | KEGG | D12729 | 1.00 | infobox |
| Revumenib | Legal status | US: ℞-only | 1.00 | infobox |
| Revumenib | License data | US DailyMed: Revumenib | 1.00 | infobox |
| Revumenib | MedlinePlus | a624077 | 1.00 | infobox |
| Revumenib | Molar mass | 630.82 g·mol−1 | 1.00 | infobox |
| Revumenib | Other names | SNDX-5613 | 1.00 | infobox |
| Revumenib | PDB ligand | OQ4 (PDBe, RCSB PDB) | 1.00 | infobox |
| Revumenib | Pronunciation | /rɪˈvuːmɛnɪb/ rih-VOO-meh-nib | 1.00 | infobox |
| Revumenib | PubChem CID | 132212657 | 1.00 | infobox |
| Revumenib | Routes of administration | By mouth | 1.00 | infobox |
| Revumenib | Trade names | Revuforj | 1.00 | infobox |
| Revumenib | UNII | LZ0M43NNF2 | 1.00 | infobox |
| Revumenib | UNII | 75HI05N8HS | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.